Your browser doesn't support javascript.
loading
Cancer History, Health Insurance Coverage, and Cost-Related Medication Nonadherence and Medication Cost-Coping Strategies in the United States.
Zhao, Jingxuan; Zheng, Zhiyuan; Han, Xuesong; Davidoff, Amy J; Banegas, Matthew P; Rai, Ashish; Jemal, Ahmedin; Yabroff, K Robin.
Afiliación
  • Zhao J; Surveillance and Health Services Research Program, American Cancer Society, Atlanta, GA, USA. Electronic address: jingxuan.zhao@cancer.org.
  • Zheng Z; Surveillance and Health Services Research Program, American Cancer Society, Atlanta, GA, USA.
  • Han X; Surveillance and Health Services Research Program, American Cancer Society, Atlanta, GA, USA.
  • Davidoff AJ; Department of Health Policy and Management, Yale School of Public Health, New Haven, CT, USA.
  • Banegas MP; The Center for Health Research, Kaiser Permanente, Portland, OR, USA.
  • Rai A; Surveillance and Health Services Research Program, American Cancer Society, Atlanta, GA, USA.
  • Jemal A; Surveillance and Health Services Research Program, American Cancer Society, Atlanta, GA, USA.
  • Yabroff KR; Surveillance and Health Services Research Program, American Cancer Society, Atlanta, GA, USA.
Value Health ; 22(7): 762-767, 2019 07.
Article en En | MEDLINE | ID: mdl-31277821
ABSTRACT

OBJECTIVES:

To evaluate the relationship between cancer history and cost-related medication nonadherence (CRN) as well as cost-coping strategies, by health insurance coverage.

METHODS:

We used the 2013 to 2016 National Health Interview Survey to identify adults aged 18 to 64 years with (n = 3599) and without (n = 56 909) a cancer history. Cost-related changes in medication use included (1) CRN, measured as skipping, taking less, or delaying medication because of cost, and (2) cost-coping strategies, measured as requesting lower cost medication or using alternative therapies to save money. Separate multivariable logistic regressions were used to calculate the adjusted odds ratios (AORs) of CRN and cost-coping strategies associated with cancer history, stratified by insurance.

RESULTS:

Cancer survivors were more likely than adults without a cancer history to report CRN (AOR 1.26; 95% confidence interval [CI] 1.10-1.43) and cost-coping strategies (AOR 1.10; 95% CI 0.99-1.19). Among the privately insured, the difference in CRN by cancer history was the greatest among those enrolled in high-deductible health plans (HDHPs) without health savings accounts (HSAs) (AOR 1.78; 95% CI 1.30-2.44). Among adults with HDHP and HSA, cancer survivors were less likely to report cost-coping strategies (AOR 0.62; 95% CI 0.42-0.90). Regardless of cancer history, CRN and cost-coping strategies were the highest for those uninsured, enrolled in HDHP without HSA, and without prescription drug coverage under their health plan (all P<.001).

CONCLUSIONS:

Cancer survivors are prone to CRN and more likely to use cost-coping strategies. Expanding options for health insurance coverage, use of HSAs for those with HDHP, and enhanced prescription drug coverage may effectively address CRN.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Gastos en Salud / Cobertura del Seguro / Cumplimiento de la Medicación / Supervivientes de Cáncer / Seguro de Salud / Neoplasias / Antineoplásicos Tipo de estudio: Health_economic_evaluation / Prognostic_studies / Qualitative_research País/Región como asunto: America do norte Idioma: En Revista: Value Health Año: 2019 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Gastos en Salud / Cobertura del Seguro / Cumplimiento de la Medicación / Supervivientes de Cáncer / Seguro de Salud / Neoplasias / Antineoplásicos Tipo de estudio: Health_economic_evaluation / Prognostic_studies / Qualitative_research País/Región como asunto: America do norte Idioma: En Revista: Value Health Año: 2019 Tipo del documento: Article